jesus, just moan moan moan moan here
Anyways, in an effort to add some value outside of bitching
Here's the front page for the term sheet for the offer. Offer is closed as yesterday - due to announce tomorrow and resume trading.G Medical Innovations Holdings Limited (ASX:GMV) is a commercial stage med tech developer of mobile health and e-health solutions.
The Company develops and markets clinical and consumer medical-grade health monitoring solutions, as well as offering support services for e-health programs.
It has two lead product offerings, Prizma and Vital Signs Monitoring System (VSMS)/G Medical Patch (GMP).
GMV’s product suite includes proprietary devices, software solutions and patient service operations:
- Prizma device – consumer focused product with freemium platform that measures vital signs includes user portal and medical report
- Prizma App – multi-tiered (+freemium) application that encases users Electronic Medical Record (EMR)
- G Medical Patch – Both VSMS and extended holter functionality (vital signs, cardiac diagnostics, Post-discharge)
- Web based portals – online portal for both healthcare professionals and consumers
- Clinical portal – continuous vital signs monitoring for enterprise providers
- Remote patient monitoring (IDTF) – through established 100% owned call centres in the USA, G Medical leverages patented wireless technologies, proprietary algorithms & information technology and service platforms to empower a new generation of consumers, patients and health care providers
The FDA recently granted over-the-counter authorisation for Prizma, setting the stage for its imminent commercial launch in the US market. This authorisation caps off a flurry of approvals for Prizma in several countries.
In response to the COVID-19 pandemic, the US FDA has granted Emergency Use Authorisation to the company’s VSMS and ECG Patch for patients undergoing COVID-19 greatment. This means the patch is eligible for reimbursement - adding to G Medical’s growing revenue profile.
This bodes well for widespread approval of the product by the FDA, which could occur as early as 2021, and accelerates the route to market.
Manufacturing ramp-up of the patch, now underway at the established facility in Israel, provides scale-up capabilities.
In an effort to expand the Company’s IDTF and remote patient monitoring services, which will increase recurring revenues, G Medical has secured six institutional deployments with leading university hospitals in the USA. Another 11 groups have now completed evaluation and will commence deployment of the services during Q3.
GMV has also engaged financial and listing advisors for a planned initial public offering on the NASDAQ Stock Exchange. The Company is targeting the NASDAQ listing date in Q3 CY2020.
